目的 评价玻璃酸钠滴眼液联合重组人表皮生长因子滴眼液雾化治疗干眼症的临床治疗效果和经济性，为临床提供有效、安全、经济的干眼症治疗方案。方法 收集天津市眼科医院2020年1月—2020年12月符合本研究制定的纳入标准的124例中、重度干眼症病例，将其分为2组：对照组接受玻璃酸钠滴眼液联合重组人表皮生长因子滴眼液局部点眼治疗，治疗组接受玻璃酸钠滴眼液联合重组人表皮生长因子滴眼液局部点眼治疗的同时，加以雾化治疗。以愈显率为疗效评价指标，并运用成本-效果法对两种不同的治疗方案进行经济学评价。结果 纳入对照组和治疗组的有效病例各62例。两组愈显率分别为56.45%、95.16%，有显著性差异（P<0.05）。采用成本-效果分析可得，以对照组为基准，增量成本效果比为7.29，治疗组每获得1%总有效率，需多支付7.29元，远低于意愿支付阈值（两种治疗方案平均总成本为276.83元），提示治疗组的成本-效果性更佳。敏感性分析显示两组的成本效果相对于药品价格及治疗费用波动稳定。结论 玻璃酸钠滴眼液联合重组人表皮生长因子滴眼液雾化治疗，能够显著提高临床疗效，具有药物经济学优势。

Objective To evaluate the clinical efficacy and economy of sodium hyaluronate eye drops combined with recombinant human epidermal growth factor eye drops in the treatment of xerophthalmia, so as to provide an effective, safe and economic treatment for xerophthalmia. Methods A total of 124 cases of moderate and severe xerophthalmia who met the inclusion criteria of this study in Tianjin Eye Hospital from January 2020 to December 2020 were collected and divided into 2 groups. The control group was treated with sodium hyaluronate eye drops combined with recombinant human epidermal growth factor eye drops for dropping, while the treatment group was treated with sodium hyaluronate eye drops combined with recombinant human epidermal growth factor eye drops for atomization and dropping. The cured + markedly effective rate was used as the evaluation index, and cost-effectiveness method was used to evaluate the economics of two different treatment schemes. Results 62 effective cases were included in the control group and the treatment group. The cured + markedly effective rate of the two groups were 56.45% and 95.16%, respectively, with significant difference (P<0.05). According to the cost-effectiveness analysis, the incremental cost-effectiveness ratio was 7.29 based on the control group, and the treatment group needed to pay 7.29 yuan more for every 1% total effective rate obtained, which was far lower than the desired payment threshold (the average total cost of the two treatment schemes was 276.83 yuan), suggesting that the treatment group had better cost-effectiveness. Sensitivity analysis showed that cost-effectiveness in both groups fluctuated steadily relative to drug prices and treatment costs. Conclusion The combination of sodium hyaluronate eye drops and recombinant human epidermal growth factor eye drops for atomization treatment can significantly improve the clinical efficacy and has the advantages of pharmacoeconomics.

R988.1